Alzamend Neuro Inc (ALZN) Stock Ticker
Market factors today
Unlock the full ALZN picture
About Alzamend Neuro Inc
Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. Its pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.
ALZN stock facts
| Ticker symbol | ALZN |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market cap | $7.0M |
| CEO | Stephan Jackman |
| Employees | 6 |
| Headquarters | Atlanta, GA, US |
| IPO date | 2021-06-15 |
| Website | www.alzamend.com |
What you can see for ALZN on Tickr
Live ALZN price chart with overlays, the options chain, implied move, IV rank, options flow and Strategy Lab, financial statements and consensus estimates, analyst ratings, catalysts, news with AI scoring, and an AI chat that has read the ALZN report.
Rankings
FAQ
What is the ticker symbol for Alzamend Neuro Inc?
The ticker symbol for Alzamend Neuro Inc is ALZN, listed on the NASDAQ.
What is ALZN?
Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. Its pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other…